Self-Complementary AAV Vector Bypassing Second-Strand Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for limb-girdle muscular dystrophy type 2E (LGMD2E) are inadequate in addressing both the need for gene restoration and reduction of fibrosis, leading to progressive muscle weakness and deterioration.
Innovation Solution
Development of self-complementary AAV (scAAV) vectors expressing the β-sarcoglycan gene, which bypass the rate-limiting step of cellular second-strand synthesis, and are designed with specific muscle promoters to enhance gene delivery and reduce fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional AAV vectors are used for gene delivery, then the vectors can be manufactured with standard processes, but the gene expression efficiency is limited due to the rate-limiting step of cellular second-strand synthesis
Solution Approach 1:
The patent changes the fundamental parameter of the AAV vector genome structure by using self-complementary DNA sequences that can directly form double-stranded DNA without requiring cellular synthesis enzymes. This parameter change bypasses the rate-limiting step of second-strand synthesis and directly achieves high-level gene expression.
Solution Approach 2:
The patent introduces an intermediary mechanism where the single-stranded AAV genome contains self-complementary sequences that mediate the formation of double-stranded DNA through intracellular hybridization rather than requiring host cell DNA synthesis machinery. This intermediary approach eliminates the bottleneck of cellular second-strand synthesis.
2Reliability
If current treatments are used for LGMD2E, then the treatment approach is simple, but the treatment is inadequate in addressing both gene restoration and fibrosis reduction
Solution Approach 1:
The patent creates a multi-functional treatment approach where the scAAV vector simultaneously delivers the β-sarcoglycan gene for restoration and includes fibrosis-reducing therapeutic sequences, allowing one treatment to address multiple aspects of the disease rather than requiring separate treatments for each condition.
Solution Approach 2:
The patent merges gene replacement therapy and anti-fibrotic therapy into a single integrated treatment regimen delivered by one scAAV vector construct, combining multiple therapeutic functions that previously required separate, complex treatment protocols.
3Strength
If muscle function is improved through gene therapy, then motor function increases, but fibrosis accumulates leading to progressive muscle deterioration
Solution Approach 1:
The patent applies preliminary anti-action by incorporating fibrosis-reducing therapeutic sequences into the scAAV vector that proactively counteract fibrosis development before it can significantly deteriorate muscle function, rather than allowing fibrosis to accumulate and then treating it separately.
Data Source
AI summary
Described herein are methods of treating muscular dystrophy comprising administering a self complementary recombinant AAV (rAAV) scAAVrh74.MHCK7.hSGCB vector, methods of expressing beta-sarcoglycan gene in a patient, pharmaceutical compositions comprising the rAAV, and methods of generating the rAAV.